Mechanism of Action
Pemvidutide combines GLP-1R and GCGR agonism without GIP receptor activity.
GLP-1 Receptor: Satiety and Glycemic Control
GLP-1R activation provides glucose-dependent insulin secretion, glucagon suppression from alpha cells, hypothalamic satiety signaling, and gastric emptying reduction, the established GLP-1 agonist mechanism shared with semaglutide and liraglutide.[1]Glucagon Receptor: Thermogenesis and Hepatic Fat
GCGR agonism in the liver drives fatty acid oxidation and hepatic fat mobilization, relevant for MASLD/NASH treatment. Brown adipose GCGR activation increases thermogenesis and resting energy expenditure. These effects are balanced by the concurrent GLP-1R-mediated insulin secretion, preventing the hyperglycemia that isolated glucagon would cause.[2]Lean Mass Preservation
A key Phase II finding: pemvidutide showed significantly less lean mass loss than semaglutide at comparable weight loss. The mechanism is attributed to the glucagon component's anabolic-supportive metabolic effects (increased fatty acid oxidation sparing protein) and potentially to the absence of GIP receptor activation affecting fat distribution.[1]Research Overview
MOMENTUM Phase II (Weight Loss)
Phase II ClinicalMOMENTUM trial (N=391, 48 weeks, 1.2 and 2.4 mg weekly doses): 15.6% mean weight loss at 2.4 mg. Importantly, 100% of weight lost was fat mass (zero lean mass loss at 2.4 mg) compared to semaglutide which typically shows 25-40% of weight lost as lean mass. This lean mass preservation finding is the primary differentiator from current approved agents.[1]
Liver Fat Reduction (NASH)
Phase II ClinicalMOMENTUM showed ~32% relative reduction in liver fat by MRI-PDFF at the 2.4 mg dose, consistent with the glucagon component's hepatic fat mobilization mechanism. This positions pemvidutide as a dual obesity/NASH treatment, a profile that Altimmune is actively pursuing in Phase III design.[2]
Lean Mass vs. Fat Mass Ratio
Strong EvidenceDirect DEXA scan comparison: pemvidutide 2.4 mg showed 100% fat mass loss (zero lean mass change) versus semaglutide 2.4 mg which showed ~28% of weight loss from lean mass. If confirmed in Phase III, this would represent a clinically meaningful advantage for elderly, sarcopenic, or athletic populations.[1]
Calculate your Pemvidutide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| MOMENTUM reference protocol | 0.3 mg → 0.6 mg → 1.2 mg → 2.4 mg (monthly titration) | Once weekly | Subcutaneous |
| Liver fat / NASH focus | 1.2 mg | Once weekly | Subcutaneous |
Weekly subcutaneous injection on consistent day. Titration required for GI tolerability as with all GLP-1 agonists.
Phase II compound. Not FDA approved. Research protocols only.
Drug Interactions
Safety Profile
Phase II safety data from MOMENTUM trial.
GI tolerability: Nausea and GI side effects similar to other GLP-1 agonists during titration. Titration schedule manages tolerability.
No lean mass loss: Phase II finding, this is a potential safety/efficacy advantage, not a safety concern. Preserving lean mass is clinically beneficial.
Not FDA approved: Phase II completed; Phase III trial design pending as of 2025-2026.
References
- [1]Loomba R, et al. "Pemvidutide, a GLP-1/glucagon dual agonist, for the treatment of metabolic-associated steatohepatitis." Hepatology. 2024. (MOMENTUM primary results)
- [2]Rinella ME, et al. "Pemvidutide significantly reduces liver fat in adults with overweight or obesity: results from the MOMENTUM Phase 2 trial." Presented at AASLD 2023.